[go: up one dir, main page]

MA29148B1 - Derives de pyrazole condenses, et procedes pour traiter des troubles lies au metabolisme - Google Patents

Derives de pyrazole condenses, et procedes pour traiter des troubles lies au metabolisme

Info

Publication number
MA29148B1
MA29148B1 MA30071A MA30071A MA29148B1 MA 29148 B1 MA29148 B1 MA 29148B1 MA 30071 A MA30071 A MA 30071A MA 30071 A MA30071 A MA 30071A MA 29148 B1 MA29148 B1 MA 29148B1
Authority
MA
Morocco
Prior art keywords
inhibitors
compounds
derivatives
methods
related disorders
Prior art date
Application number
MA30071A
Other languages
English (en)
Inventor
Douglas P Boatman
Thomas O Schrader
Graeme Semple
Philip J Skinner
Jae-Kyu Jung
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MA29148B1 publication Critical patent/MA29148B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'INVENTION CONCERNE CERTAINS DÉRIVÉS DE PYRAZOLE CONDENSÉS DE FORMULE (IA), ET DES SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CES DÉRIVÉS, LESDITS DÉRIVÉS ET SELS PRÉSENTANT DES PROPRIÉTÉS PHARMACOLOGIQUES UTILES, PAR EXEMPLE, EN TANT QU'AGONISTES DU RÉCEPTEUR RUP25. CETTE INVENTION CONCERNE ÉGALEMENT DES COMPOSITIONS PHARMACEUTIQUES CONTENANT LES COMPOSÉS DE L'INVENTION, ET DES PROCÉDÉS D'UTILISATION DES COMPOSÉS ET COMPOSITIONS SELON L'INVENTION POUR TRAITER DES TROUBLES LIÉS AU MÉTABOLISME, Y COMPRIS LA DYSLIPIDEMIE, L'ATHÉROSCLÉROSE, LES MALADIES CORONARIENNES, LA RÉSISTANCE À L'INSULINE, LE DIABÈTE DE TYPE 2, LE SYNDROME X, ET ANALOGUE. DE PLUS, LA PRÉSENTE INVENTION CONCERNE L'UTILISATION DESDITS COMPOSÉS EN ASSOCIATION AVEC D'AUTRES AGENTS ACTIFS TELS QUE CEUX APPARTENANT À LA CLASSE DES INHIBITEURS DE L'$G(A)-GLUCOSIDASE, DES INHIBITEURS DE L'ALDOSE RÉDUCTASE, DES BIGUANIDES, DES INHIBITEURS DE LA HMG-COA RÉDUCTASE, DES INHIBITEURS DE LA SYNTHÈSE DE SQUALÈNE, DES FIBRATES, DES RENFORÇATEURS DU CATABOLISME DES LDL, DES INHIBITEURS DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE (ACE), DES RENFORÇATEURS DE LA SÉCRÉTION D'INSULINE, DES ANTAGONISTES DU RÉCEPTEUR DP, ET ANALOGUE.
MA30071A 2004-12-23 2007-07-12 Derives de pyrazole condenses, et procedes pour traiter des troubles lies au metabolisme MA29148B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63866804P 2004-12-23 2004-12-23
US67652105P 2005-04-29 2005-04-29

Publications (1)

Publication Number Publication Date
MA29148B1 true MA29148B1 (fr) 2008-01-02

Family

ID=36593187

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30071A MA29148B1 (fr) 2004-12-23 2007-07-12 Derives de pyrazole condenses, et procedes pour traiter des troubles lies au metabolisme

Country Status (24)

Country Link
US (3) US7241792B2 (fr)
EP (1) EP1831178A2 (fr)
JP (1) JP2008525476A (fr)
KR (1) KR20070088808A (fr)
CN (2) CN102321024A (fr)
AR (1) AR055015A1 (fr)
AU (1) AU2005319121A1 (fr)
BR (1) BRPI0519262A2 (fr)
CA (1) CA2589648A1 (fr)
CU (1) CU23691B7 (fr)
EA (1) EA013184B1 (fr)
GE (1) GEP20105126B (fr)
GT (1) GT200500379A (fr)
HN (1) HN2005036256A (fr)
IL (1) IL183654A0 (fr)
MA (1) MA29148B1 (fr)
NI (1) NI200700161A (fr)
NO (1) NO20073766L (fr)
NZ (1) NZ555721A (fr)
PA (1) PA8658301A1 (fr)
PE (1) PE20060949A1 (fr)
TN (1) TNSN07236A1 (fr)
TW (1) TW200635904A (fr)
WO (1) WO2006069242A2 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
CN1882557A (zh) * 2003-11-21 2006-12-20 艾尼纳制药公司 4－氧代－4,5－二氢－呋喃－2－羧酸衍生物及其治疗代谢相关病症的方法
PE20060949A1 (es) * 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
PL1901731T3 (pl) 2005-06-28 2011-08-31 Merck Sharp & Dohme Agoniści receptora niacyny, kompozycje zawierające te związki i sposoby leczenia
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO2010003624A2 (fr) 2008-07-09 2010-01-14 Sanofi-Aventis Composés hétérocycliques, leurs procédés de préparation, médicaments comprenant lesdits composés et leur utilisation
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
IN2012DN02474A (fr) 2009-08-28 2015-08-21 Arena Pharm Inc
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
WO2011157827A1 (fr) 2010-06-18 2011-12-22 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
CA2827057C (fr) 2011-02-25 2022-06-07 Arena Pharmaceuticals, Inc. Formes cristallines et procedes de preparation d'azacycles condenses (modulateurs des recepteurs des cannabinoides)
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
WO2012116278A1 (fr) * 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Modulateurs des récepteurs de cannabinoïdes
CN109970708B (zh) 2011-02-25 2022-06-21 艾尼纳制药公司 大麻素受体调节剂
WO2012120057A1 (fr) 2011-03-08 2012-09-13 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
EP2766349B1 (fr) 2011-03-08 2016-06-01 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683702B1 (fr) 2011-03-08 2014-12-24 Sanofi Nouveaux dérivés de phényle-oxathiazine substitués, leur procédé de fabrication, médicament contenant ces liaisons et son utilisation
WO2012120051A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
EP2683701B1 (fr) 2011-03-08 2014-12-24 Sanofi Dérivés d'oxathiazine substitués par des groupes de benzyle-méthyles ou d'hétéro-méthyles, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
CA2878625A1 (fr) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comportant des statines, des biguanides et d'autres agents pour reduire un risque cardiometabolique
BR112019023214A2 (pt) 2017-05-08 2020-05-26 Arena Pharmaceuticals, Inc. Compostos e métodos para tratamento de dor visceral

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3105336A (en) * 1961-05-16 1963-10-01 Package Machinery Co Converting wrapping machines to wrap different size articles
US4613610A (en) * 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US5134155A (en) 1991-08-08 1992-07-28 Ortho Pharmaceutical Corporation Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors
ES2281186T3 (es) * 1998-08-07 2007-09-16 Novartis Vaccines And Diagnostics, Inc. Pirazoles como moduladores de receptores de estrogenos.
JP4292742B2 (ja) 2000-03-09 2009-07-08 小野薬品工業株式会社 インドール誘導体、その製造方法および用途
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
US6410583B1 (en) 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
WO2002094830A2 (fr) 2001-05-23 2002-11-28 Merck Frosst Canada & Co. Derives de dihydropyrrolo[1,2-a]indole et de tetrahydropyrido[1,2-a]-indole utilises comme antagonistes des recepteurs de prostaglandine d2
AU2002345388A1 (en) 2001-06-27 2003-03-03 Rs Tech Corp. New chiral salen catalyst and methods for the preparation of chiral compounds from racemic epoxides by using new catalyst
CA2459515A1 (fr) 2001-09-07 2003-03-20 Kazuhiko Torisu Derives d'indole
DE10148617A1 (de) 2001-09-25 2003-04-24 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
ES2365985T3 (es) 2002-03-19 2011-10-14 Ono Pharmaceutical Co., Ltd. Compuestos de ácido carboxílico y fármacos que contienen los compuestos como ingrediente activo.
WO2004033431A2 (fr) 2002-10-04 2004-04-22 Arena Pharmaceuticals, Inc. Hydroxypyrazoles et methodes prophylactiques ou de traitement de troubles lies au metabolisme
EP1551403B1 (fr) * 2002-10-10 2009-04-29 Arena Pharmaceuticals, Inc. Derives d'acide 2h-pyrazole-3-carboxylique substitue en 5 utilises en tant qu'agents antilipotyques pour le traitement de troubles metaboliques, tels que la dyslipidemie
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
WO2005011677A1 (fr) 2003-06-13 2005-02-10 Arena Pharmaceuticals, Inc. Derives d'acide 2h-pyrazol-3- carboxylique substitues en 5 utilises comme agonistes du recepteur de l'acide nicotinique rup25 pour le traitement des dyslipidemies et des pathologies apparentees
GB0319126D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
GB0319124D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
TWI258478B (en) * 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
BRPI0507604A (pt) 2004-02-14 2007-07-03 Smithkline Beecham Corp medicamentos com atividade de receptor hm74a
PE20060949A1 (es) * 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina

Also Published As

Publication number Publication date
WO2006069242A3 (fr) 2006-08-31
PA8658301A1 (es) 2006-10-13
CA2589648A1 (fr) 2006-06-29
GEP20105126B (en) 2010-12-10
TW200635904A (en) 2006-10-16
US20070073062A1 (en) 2007-03-29
US20090258892A1 (en) 2009-10-15
BRPI0519262A2 (pt) 2009-01-06
CU20070144A7 (es) 2010-01-22
US7612106B2 (en) 2009-11-03
EA200701361A1 (ru) 2007-12-28
CN102321024A (zh) 2012-01-18
IL183654A0 (en) 2007-09-20
KR20070088808A (ko) 2007-08-29
GT200500379A (es) 2006-10-25
NO20073766L (no) 2007-09-21
EP1831178A2 (fr) 2007-09-12
AR055015A1 (es) 2007-08-01
NI200700161A (es) 2008-04-21
WO2006069242A2 (fr) 2006-06-29
EA013184B1 (ru) 2010-02-26
PE20060949A1 (es) 2006-10-11
CU23691B7 (es) 2011-09-21
CN102311378A (zh) 2012-01-11
US20060205955A1 (en) 2006-09-14
JP2008525476A (ja) 2008-07-17
TNSN07236A1 (en) 2008-11-21
HN2005036256A (es) 2010-02-08
US7241792B2 (en) 2007-07-10
AU2005319121A1 (en) 2006-06-29
NZ555721A (en) 2011-02-25

Similar Documents

Publication Publication Date Title
MA29148B1 (fr) Derives de pyrazole condenses, et procedes pour traiter des troubles lies au metabolisme
WO2004033431A3 (fr) Hydroxypyrazoles et methodes prophylactiques ou de traitement de troubles lies au metabolisme
MA33056B1 (fr) Composition pharmaceutique solide comprenant de l'amlodipine et du losartan et son procede de fabrication
MA33886B1 (fr) Dérivés substitués d'acide carbamoylméthylamino-acétique utilisés comme nouveaux inhibiteurs de nep
MA30602B1 (fr) Modulateurs du metabolisme, et traitement de troubles au moyen de ces modulateurs
MA30722B1 (fr) Utilisation de derives de l'adenosine en tant qu'agonistes du recepteurs a2a
MA27883A1 (fr) Derives de pyrido [2,1-a] isoquinoline utilises comme inhibiteurs de dpp-iv
MA27728A1 (fr) Antagonistes des recepteurs de cgrp
MA31087B1 (fr) Derives d'amide et d'ester d'indazolyle pour traiter des troubles medies par le recepteur de glucocorticoïde.
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA30412B1 (fr) Composés Pharmaceutiques
MA30652B1 (fr) Composes organiques
MA31763B1 (fr) Inhibiteurs de kinase de type polo
MA29799B1 (fr) Administration d'inhibiteurs de dipeptidyl peptidase
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
MA31373B1 (fr) Composes amino-heterocycliques
MA28175A1 (fr) Composes organiques
MY140410A (en) Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA31432B1 (fr) Metabolites de derives de (thio) carbamoyl-cyclohexane
MA30089B1 (fr) (arylsulfonyl)-pyrasolopiperidines
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA30693B1 (fr) Derives de la purine utilises en tant qu'agonistes de l'a2a